Hexarelin — Indexed Studies

Cortistatin-8, a synthetic cortistatin-derived ghrelin receptor ligand, does not modify the endocrine responses to acylated ghrelin or hexarelin in humans.

Prodam F, Benso A, Gramaglia E et al.

d-Lys-GHRP-6 does not modify the endocrine response to acylated ghrelin or hexarelin in humans.

Benso A, Prodam F, Lucatello B et al.

There are no acute cardiac effects of a single iv dose of human ghrelin in severe growth hormone deficient patients.

Janssen JA, Poldermans D, Hofland LJ et al.

Age-related differences in growth hormone (GH) regulation during strenuous exercise.

de Vries WR, Lambers M, van Zanten DP et al.

Hexarelin decreases slow-wave sleep and stimulates the secretion of GH, ACTH, cortisol and prolactin during sleep in healthy volunteers.

Frieboes RM, Antonijevic IA, Held K et al.

Cyclical Cushing's syndrome in a patient with a bronchial neuroendocrine tumor (typical carcinoid) expressing ghrelin and growth hormone secretagogue receptors.

Arnaldi G, Mancini T, Kola B et al.

Effects of cortistatin-14 and somatostatin-14 on the endocrine response to hexarelin in humans.

Benso A, Gottero C, Prodam F et al.

GHRP-6 is able to stimulate cortisol and ACTH release in patients with Cushing's disease: comparison with DDAVP.

Oliveira JH, Vieira JG, Abucham J et al.

A practical approach to the diagnosis of growth hormone (GH) deficiency in patients transitioning to adulthood using GH stimulation testing.

Styne DM

Age-related variations of the GH response to GH secretagogues in humans.

Gottero C, Benso A, Prodam F et al.

Effects of glucose, free fatty acids or arginine load on the GH-releasing activity of ghrelin in humans.

Broglio F, Benso A, Gottero C et al.

Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery.

Broglio F, Guarracino F, Benso A et al.

GH-independent cardiotropic activities of hexarelin in patients with severe left ventricular dysfunction due to dilated and ischemic cardiomyopathy.

Imazio M, Bobbio M, Broglio F et al.

Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans.

Maccario M, Veldhuis JD, Broglio F et al.

Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans.

Broglio F, Arvat E, Benso A et al.

Biologic activities of growth hormone secretagogues in humans.

Ghigo E, Arvat E, Giordano R et al.

Growth hormone-independent cardiotropic activities of growth hormone-releasing peptides in normal subjects, in patients with growth hormone deficiency, and in patients with idiopathic or ischemic dilated cardiomyopathy.

Broglio F, Benso A, Valetto MR et al.

Recombinant human IGF-I does not modify the ACTH and cortisol responses to hCRH and hexarelin, a peptidyl GH secretagogue, in humans.

Gianotti L, Ramunni J, Lanfranco F et al.

Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.

Arvat E, Maccario M, Di Vito L et al.

The diagnosis of growth hormone deficiency (GHD) in successfully treated acromegalic patients.

Murray RD, Peacey SR, Rahim A et al.

Effects of alprazolam, a benzodiazepine, on the ACTH-, GH- and PRL-releasing activity of hexarelin, a synthetic peptidyl GH secretagogue (GHS), in patients with simple obesity and in patients with Cushing's disease.

Grottoli S, Arvat E, Gauna C et al.

Interaction between glucagon and hexarelin, a peptidyl GH secretagogue, on somatotroph and corticotroph secretion in humans.

Arvat E, Maccagno B, Ramunni J et al.

Endocrine activities of alexamorelin (Ala-His-d-2-methyl-Trp-Ala-Trp-d-Phe-Lys-NH2), a synthetic GH secretagogue, in humans.

Broglio F, Benso A, Gottero C et al.

Alprazolam, a benzodiazepine, blunts but does not abolish the ACTH and cortisol response to hexarelin, a GHRP, in obese patients.

Grottoli S, Arvat E, Gauna C et al.

Growth hormone secretagogues: mechanism of action and use in aging.

Fuh VL, Bach MA

Does desensitization to hexarelin occur?

Rahim A, Shalet SM

Desmopressin and hexarelin tests in alcohol-induced pseudo-Cushing's syndrome.

Coiro V, Volpi R, Capretti L et al.

Role of food intake in the modulation of hexarelin-induced growth hormone release in normal human subjects.

De Marinis L, Mancini A, Valle D et al.

The negative GH auto-feedback in childhood: effects of rhGH and/or GHRH on the somatotroph response to GHRH or hexarelin, a peptidyl GH secretagogue, in children.

Bellone J, Bellone S, Aimaretti G et al.

Activity of GH/IGF-I axis in patients with dilated cardiomyopathy.

Benso A, Broglio F, Gottero C et al.

Hexarelin promotes the survival of retinal ganglion cells after optic nerve transection.

Chow KBS

Identification of alexamorelin consumption biomarkers using human hepatocyte incubations and high-resolution mass spectrometry.

Pobee E, Daziani G, Gameli PS et al.

Pharmacological targeting of the hyper-inflammatory response to SARS-CoV-2-infected K18-hACE2 mice using a cluster of differentiation 36 receptor modulator.

Gauvin J, Huynh DN, Dubuc I et al.

Revealing the interaction between peptide drugs and permeation enhancers in the presence of intestinal bile salts.

Hossain S, Kneiszl R, Larsson P

Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway.

Guan C, Li C, Shen X et al.

Protective Effects of Hexarelin and JMV2894 in a Human Neuroblastoma Cell Line Expressing the SOD1-G93A Mutated Protein.

Meanti R, Licata M, Rizzi L et al.

Using Synchrotron Radiation Imaging Techniques to Elucidate the Actions of Hexarelin in the Heart of Small Animal Models.

Waddingham MT, Tsuchimochi H, Sonobe T et al.

Hexarelin modulates lung mechanics, inflammation, and fibrosis in acute lung injury.

Zambelli V, Rizzi L, Delvecchio P et al.

Hexarelin attenuates abdominal aortic aneurysm formation by inhibiting SMC phenotype switch and inflammasome activation.

Jiang B, Wang M, Li X et al.

Effect of paracellular permeation enhancers on intestinal permeability of two peptide drugs, enalaprilat and hexarelin, in rats.

Dahlgren D, Olander T, Sjöblom M et al.

Hexarelin Modulation of MAPK and PI3K/Akt Pathways in Neuro-2A Cells Inhibits Hydrogen Peroxide-Induced Apoptotic Toxicity.

Meanti R, Rizzi L, Bresciani E et al.

Stimulation of endogenous pulsatile growth hormone secretion by activation of growth hormone secretagogue receptor reduces the fat accumulation and improves the insulin sensitivity in obese mice.

Huang Z, Lu X, Huang L et al.

Ghrelin receptor agonist hexarelin attenuates antinociceptive tolerance to morphine in rats.

Baser T, Ozdemir E, Filiz AK et al.

Hexarelin targets neuroinflammatory pathways to preserve cardiac morphology and function in a mouse model of myocardial ischemia-reperfusion.

McDonald H, Peart J, Kurniawan ND et al.

The In Vivo Effect of Transcellular Permeation Enhancers on the Intestinal Permeability of Two Peptide Drugs Enalaprilat and Hexarelin.

Dahlgren D, Sjöblom M, Hedeland M et al.

Hexarelin protects cardiac H9C2 cells from angiotensin II-induced hypertrophy via the regulation of autophagy.

Agbo E, Li MX, Wang YQ et al.

Hexarelin attenuates atherosclerosis via inhibiting LOX-1-NF-κB signaling pathway-mediated macrophage ox-LDL uptake in ApoE(-/-) mice.

Cheng XL, Ding F, Wang DP et al.

Modulation of PTEN by hexarelin attenuates coronary artery ligation-induced heart failure in rats.

Agbo E, Liu D, Li M et al.

Characterization of a third ghrelin receptor, GHS-R3a, in channel catfish reveals novel expression patterns and a high affinity for homologous ligand.

Small BC, Quiniou SMA, Kaiya H et al.

Zebrafish (Danio rerio) water tank model for the investigation of drug metabolism: Progress, outlook, and challenges.

Sardela VF, Anselmo CS, Nunes IKDC et al.